Third, our patient population with prostate cancers is older than that in similar studies and likely demonstrated more advanced disease, which could theoretically bias the interpretation of our data in relation to existing literature, as the prevalence of PTEN loss is higher than that reported in similar cohorts from the region and on the upper end of rates reported from Western countries. The gene discussed is PTEN; the disease is prostate carcinoma.